KDR and cancer: FGF2 has been heavily implicated as a proangiogenic factor, promoting endothelial proliferation and migration following FGFR1/2 signalling and VEGF/angiopoietin 2 secretion [82], and has been shown to mediate resistance to VEGFR targeted therapy in cancer [83].